Fresh analysis suggests that patients who stop using new slimming jabs like semaglutide or tirzepatide can put back on lost weight far faster than those who stop traditional diet and exercise plans.
Findings released in a major health publication points out that while obese people often shed substantial amounts of their body weight while on the medication, the mass comes back at an average rate of 0.8 kg per month upon discontinuation.
"Individuals buying such treatments should be cognizant of the potential of fast rebound weight gain when the medication ends," stated researcher Dr. Susan Jebb.
That rate of recovery implies a reversion to pre-treatment weight within about a year and a half.
Comparing Approaches
The research, which reviewed 37 of studies involving over 9,000 of participants, contrasted the outcomes of GLP-1 agonists with other pills.
Researchers emphasize that individuals who lose weight through lifestyle changes alone generally experience a less rapid weight regain—around 100 grams monthly—after stopping.
Understanding the Quick Regain
Experts believe the way of the jabs is key to understanding the accelerated rebound.
These medications copy a body's own chemical called GLP-1, which controls feelings of fullness.
"Sustained high doses of the hormone concentrations far above than normal may cause the system to generate a reduced amount of its own natural hormone, and could diminish sensitivity to its actions," noted Dr. Adam Collins, a dietetics specialist.
"Discontinuation of this GLP-1 'fix' means hunger is uncontrolled, making overeating a significant risk."
A Chronic Issue?
The NHS advise the jabs for individuals with obesity-related medical conditions, accompanied by recommended lifestyle changes.
Many experts argue that, due to the high risk of relapse, the treatment is often long-term.
This opinion is reinforced by pharmaceutical companies, who say that the results "emphasize the long-term character of obesity," comparing it to managing diseases like high blood pressure.
Patient Testimonies
People who have stopped the jabs describe a powerful return of cravings.
"It felt as if a switch that goes on and you become ravenous," recalled a patient.
The struggle is worsened if individuals have not adopted lasting dietary or behavioural changes during therapy.
Widespread Interest
Recent estimates suggest that a significant number of people in the UK have used these injections in the past year, with interest being substantial.
- Adoption is more common among females than males.
- The 40s and 50s age group shows the highest usage rates.
- Many access the drugs through private healthcare rather than the NHS.
Finally, researchers stress that while GLP-1 drugs are effective tools for weight loss, they are not a magic solution and long-term success hinges on combined lifestyle changes.
